DDInter1840 DDInter737
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Trabectedin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fingolimod
Trabectedin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Trabectedin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Trabectedin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Trabectedin {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) interacts with {v} (Gene) CYP4F2
CYP4F2 {u} (Gene) is bound by {v} (Compound) Fingolimod
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is downregulated by {v} (Compound) Nizatidine
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Trabectedin {u} (Compound) causes {v} (Side Effect) Traumatic liver injury
Traumatic liver injury {u} (Side Effect) is caused by {v} (Compound) Tizanidine
Tizanidine {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Trabectedin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Trabectedin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Trabectedin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Trabectedin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Trabectedin (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) interacts with CYP4F2 (Gene) and CYP4F2 (Gene) is bound by Fingolimod (Compound)
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may lead to a major life threatening interaction when taken with Fingolimod
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is downregulated by Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Trabectedin (Compound) causes Traumatic liver injury (Side Effect) and Traumatic liver injury (Side Effect) is caused by Tizanidine (Compound) and Tizanidine may lead to a major life threatening interaction when taken with Fingolimod